Welcome to our dedicated page for BEIGF SEC filings (Ticker: BEIGF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on BEIGF's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into BEIGF's regulatory disclosures and financial reporting.
The issuer reported a proposed sale of ADS securities on NASDAQ, filed on 06/08/2026. The filing lists 36,900.64 ADS and references a 06/05/2026 transaction date tied to Restricted Stock Vesting Under a Registered Plan.
The issuer reported a proposed sale of ADS securities on NASDAQ, filed on 06/08/2026. The filing lists 36,900.64 ADS and references a 06/05/2026 transaction date tied to Restricted Stock Vesting Under a Registered Plan.
ONC submitted a Form 144 notice indicating 871 ADS referenced under its securities information and a restricted stock vesting event on 06/05/2026. The excerpt lists three recent ADS dispositions: 332 ADS on 05/13/2026 for $103,159.04, 332 ADS on 04/08/2026 for $103,447.88, and 341 ADS on 03/11/2026 for $102,300.00.
ONC submitted a Form 144 notice indicating 871 ADS referenced under its securities information and a restricted stock vesting event on 06/05/2026. The excerpt lists three recent ADS dispositions: 332 ADS on 05/13/2026 for $103,159.04, 332 ADS on 04/08/2026 for $103,447.88, and 341 ADS on 03/11/2026 for $102,300.00.
The issuer reported a Form 144 notice for 1,367 ADS dated 06/05/2026, tied to restricted stock vesting under a registered plan. The form lists Morgan Stanley Smith Barney LLC as the broker and shows transaction details including an amount 368,246.83 and a reference number 54,885,669.
The issuer reported a Form 144 notice for 1,367 ADS dated 06/05/2026, tied to restricted stock vesting under a registered plan. The form lists Morgan Stanley Smith Barney LLC as the broker and shows transaction details including an amount 368,246.83 and a reference number 54,885,669.
ONC submitted a Form 144 notice reporting a proposed sale of 1,484 ADS. The filing lists the trade date or vesting date as 06/05/2026 and a filing/check date of 06/08/2026. The securities are described as Restricted Stock Vesting Under a Registered Plan and the broker listed is Morgan Stanley Smith Barney LLC with NASDAQ noted as the market.
ONC submitted a Form 144 notice reporting a proposed sale of 1,484 ADS. The filing lists the trade date or vesting date as 06/05/2026 and a filing/check date of 06/08/2026. The securities are described as Restricted Stock Vesting Under a Registered Plan and the broker listed is Morgan Stanley Smith Barney LLC with NASDAQ noted as the market.
ONC submitted a Form 144 notice reporting an intended sale of 4,940 ADS relating to Restricted Stock Vesting Under a Registered Plan. The filing lists Morgan Stanley Smith Barney LLC Executive Financial Services as the broker and shows dates 06/05/2026 and 06/08/2026.
ONC submitted a Form 144 notice reporting an intended sale of 4,940 ADS relating to Restricted Stock Vesting Under a Registered Plan. The filing lists Morgan Stanley Smith Barney LLC Executive Financial Services as the broker and shows dates 06/05/2026 and 06/08/2026.
BeOne Medicines Ltd. director Yi Qingqing reported a small share disposition linked to equity compensation. On June 1, 2026, Yi disposed of 235 American Depositary Shares of BeOne Medicines at $279.13 per ADS. According to the disclosure, this sale was carried out under a mandatory tax withholding provision in Yi’s restricted share unit (RSU) agreement in connection with RSU vesting, rather than as a discretionary open-market trade. Following the transactions reported, Yi holds 24,271 Ordinary Shares directly, reflecting a continuing equity stake in the company.
BeOne Medicines Ltd. director Yi Qingqing reported a small share disposition linked to equity compensation. On June 1, 2026, Yi disposed of 235 American Depositary Shares of BeOne Medicines at $279.13 per ADS. According to the disclosure, this sale was carried out under a mandatory tax withholding provision in Yi’s restricted share unit (RSU) agreement in connection with RSU vesting, rather than as a discretionary open-market trade. Following the transactions reported, Yi holds 24,271 Ordinary Shares directly, reflecting a continuing equity stake in the company.
BeOne Medicines Ltd. director Alessandro Riva reported a small tax‑related share sale. On 2026-05-22, he sold 212 American Depositary Shares of BeOne Medicines in an open-market transaction at an average price of $309.5142 per ADS. A footnote explains the sale was mandated under a tax withholding provision tied to the vesting of a restricted share unit award, meaning it was executed to cover tax obligations rather than as a discretionary portfolio move. Each American Depositary Share represents 13 Ordinary Shares. After these transactions, a holding entry shows Riva with 54,184 Ordinary Shares held directly.
BeOne Medicines Ltd. director Alessandro Riva reported a small tax‑related share sale. On 2026-05-22, he sold 212 American Depositary Shares of BeOne Medicines in an open-market transaction at an average price of $309.5142 per ADS. A footnote explains the sale was mandated under a tax withholding provision tied to the vesting of a restricted share unit award, meaning it was executed to cover tax obligations rather than as a discretionary portfolio move. Each American Depositary Share represents 13 Ordinary Shares. After these transactions, a holding entry shows Riva with 54,184 Ordinary Shares held directly.
BeOne Medicines director Margaret Dugan disposed American Depositary Shares to satisfy tax withholding on vested restricted share units. She sold 212 American Depositary Shares at an average price of $309.6017 per ADS in an open-market transaction tied to a mandatory tax provision in her RSU award agreement.
Each American Depositary Share represents 13 Ordinary Shares. After these transactions, she holds 54,184 Ordinary Shares directly and no American Depositary Shares, indicating she retained a substantial equity position while covering tax obligations from the RSU vesting.
BeOne Medicines director Margaret Dugan disposed American Depositary Shares to satisfy tax withholding on vested restricted share units. She sold 212 American Depositary Shares at an average price of $309.6017 per ADS in an open-market transaction tied to a mandatory tax provision in her RSU award agreement.
Each American Depositary Share represents 13 Ordinary Shares. After these transactions, she holds 54,184 Ordinary Shares directly and no American Depositary Shares, indicating she retained a substantial equity position while covering tax obligations from the RSU vesting.
BeOne Medicines Ltd. director Sanders Corazon (Corsee) D. reported a small tax-related share sale. On May 22, 2026, the director sold 212 American Depositary Shares at $309.5896 per ADS, with each ADS representing 13 Ordinary Shares. The sale was mandated under a tax withholding provision tied to the vesting of a restricted share unit award, rather than a discretionary market trade.
Following this transaction, the director holds 54,470 Ordinary Shares directly and no American Depositary Shares. The footnotes state that the restricted share units vest based on service on the board, with potential accelerated vesting upon a change in control or certain termination events.
BeOne Medicines Ltd. director Sanders Corazon (Corsee) D. reported a small tax-related share sale. On May 22, 2026, the director sold 212 American Depositary Shares at $309.5896 per ADS, with each ADS representing 13 Ordinary Shares. The sale was mandated under a tax withholding provision tied to the vesting of a restricted share unit award, rather than a discretionary market trade.
Following this transaction, the director holds 54,470 Ordinary Shares directly and no American Depositary Shares. The footnotes state that the restricted share units vest based on service on the board, with potential accelerated vesting upon a change in control or certain termination events.